Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IBD IN 2018

New approaches along the IBD course: diet, tight control and stem cells

Important studies published in 2018 highlight novel therapeutic strategies along the disease course of IBD, including potential specific dietary modifications at early stages and treatment with adipose-derived stem cells in perianal Crohn’s disease. A treat-to-target approach that involves proactive serial monitoring of inflammatory biomarkers can assist in timely treatment escalation and promises improved patient outcomes.

Key advances

  • Specific mixtures of macronutrients and emulsifiers within the diet affect intestinal permeability, gut microbiota density and predispose to intestinal inflammation in IBD2

  • Allogeneic expanded adipose-derived stem cells result in long-term clinical and radiological healing in patients with treatment-refractory perianal Crohn’s disease3

  • An approach of tight control, using faecal calprotectin and C-reactive protein measurements to guide treatment escalation, resulted in improved endoscopic and clinical outcomes in patients with Crohn’s disease4

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: New targets and strategies along the course of IBD.

References

  1. 1.

    Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018).

    Article  Google Scholar 

  2. 2.

    Llewellyn, S. R. et al. Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in mice. Gastroenterology 154, 1037–1046 (2018).

    Article  Google Scholar 

  3. 3.

    Panes, J. et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology 154, 1334–1342 (2018).

    Article  Google Scholar 

  4. 4.

    Colombel, J. F. et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779–2789 (2018).

    Article  Google Scholar 

  5. 5.

    Chassaing, B. et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519, 92–96 (2015).

    CAS  Article  Google Scholar 

  6. 6.

    Panes, J. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388, 1281–1290 (2016).

    Article  Google Scholar 

  7. 7.

    D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).

    Article  Google Scholar 

  8. 8.

    Khanna, R. et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet 386, 1825–1834 (2015).

    CAS  Article  Google Scholar 

  9. 9.

    Peyrin-Biroulet, L. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am. J. Gastroenterol. 110, 1324–1338 (2015).

    Article  Google Scholar 

  10. 10.

    Reinisch, W. et al. 325 - Factors driving treatment escalation in Crohn’s disease in the Calm trial. Gastroenterology 154, S-81 (2018).

Download references

Acknowledgements

The authors thank Whitney Tang for assistance with preparing the figure.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Siew C. Ng.

Ethics declarations

Competing interests

S.C.N. has received consulting and speaker fees from AbbVie, Ferring, Janssen, Menarini and Takeda, served as a Scientific Advisory Board member for AbbVie, Ferring and Takeda and received research grants from AbbVie, Ferring and Janssen. A.N.A. has served as a Scientific Advisory Board member for Abbvie and Gilead and received research grants from Pfizer and Merck.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ng, S.C., Ananthakrishnan, A.N. New approaches along the IBD course: diet, tight control and stem cells. Nat Rev Gastroenterol Hepatol 16, 82–84 (2019). https://doi.org/10.1038/s41575-018-0088-4

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing